| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-005 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2023 年度股东大会审议通过：自 2024 年 5 月 23 日至 2024 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 421,300 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：三家全资子公司：青岛润达、鑫海润邦、青岛益信；两 家控股子公司：云南康泰、济南润达。被担保人非上市公司关联人。 本次担保金额及 ...

Summary of Runda Medical Conference Call Company Overview - **Company**: Runda Medical - **Industry**: Medical AI Key Points and Arguments Recent Developments in Medical AI - Runda AI has made significant advancements in the medical AI sector, collaborating with Huawei to launch an AI medical integration machine based on DeepMind technology and releasing the "Guardian Engine" smart body in partnership with West China Hospital [3][4] - The company introduced a dedicated model for interpreting test reports in 2021 and launched the first generation of its medical large model, "Good Doctor Assistant," in September 2023, with a second generation expected in September 2024 after 28 iterations [3][4] - Runda AI's integration machine simplifies hospital procurement processes and is particularly well-received by top provincial hospitals and city-level hospitals in economically developed regions [3][5] Market Expansion and Projections - Runda AI anticipates 2025 to be a breakthrough year for commercialization, driven by policy support and technological advancements, with plans to expand market coverage and deepen collaborations with top hospitals [3][7] - The company has signed contracts with over 100 tier-3 hospitals and is focusing on the clinical application of its products [3][7] AI Model Applications - The applications of Runda AI's medical large model are categorized into three levels: 1. Basic Q&A functions via hardware servers 2. Pre-set instruction functions for medical record writing and quality control 3. Comprehensive disease management models developed in collaboration with hospitals [10][15] Competitive Advantages - Runda AI is the first company to launch a medical integration machine, with a commercial process that began in 2023 and is accelerating in 2024. The company has developed multiple functional modules tailored for clinical scenarios, providing a competitive edge [9][16] - The integration machine's pricing strategy includes various versions based on functionality and computational power, targeting high-end hospitals with significant investment capabilities [6][8] Impact of AI Integration Machine - The release of the AI integration machine has improved customer education and trust in AI technology, streamlining procurement processes for hospitals [5][11] - Following the support from the National Health Commission for AI clinical use, there has been a surge in orders post-Chinese New Year, indicating a significant acceleration in AI business industrialization in 2025 compared to 2024 [11][12] Collaboration and Development - Runda AI collaborates closely with Huawei to design and plan new AI models, enhancing performance and optimizing human-computer interaction [19] - The company is also working on various specialized applications, such as emergency chest pain models with Qilu Hospital, aimed at improving rapid diagnosis capabilities and reducing misdiagnosis rates [14][17] Future Plans and Product Development - Runda AI is actively developing C-end products, including the "Health Xiao Mei" product in collaboration with Meinian Health, which has been launched in hundreds of health check-up institutions [23] - The company is also exploring further integration with Huawei's mobile and wearable devices, with plans for data integration and health risk analysis [24][26] Operational Efficiency - The deployment speed of AI models in hospitals has significantly improved, reducing the average delivery time from two months to three days through automation and process optimization [18] Additional Important Information - Runda AI's AI medical record generation model learns from hospital writing habits, allowing doctors to confirm records in seconds, significantly enhancing efficiency and quality [13] - The company is addressing the challenges of data integration for AI applications, emphasizing the need for structured data to provide accurate decision-making support [12]

Group 1 - The Fuzhou Xintou Zhi Kairuikang Venture Capital Fund Partnership (Limited Partnership) has been established recently, focusing on private equity investment, investment management, and asset management activities [1] - The company is co-funded by Run Da Medical and other entities, indicating a collaborative investment approach [1]

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-004 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于上月为子公司担保的进展情况公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）为支持上海润达医疗科技股份有限公司（以下简称"公司"）全 资及控股子公司的发展，解决其流动资金短缺问题，经公司董事会及 2023 年度股东大会审议通过：自 2024 年 5 月 23 日至 2024 年度股东大会召开之 日期间，为公司全资及控股子公司向（类）金融机构申请总额不超过人民币 421,300 万元的授信额度提供连带责任保证担保，控股子公司其他股东提供 对等担保或为公司提供足额反担保，公司实际承担出资比例对应的担保金额。 被担保人名称：七家全资子公司：杭州润达、惠中医疗、惠中生物、浙 江中鼎、杭州铭和元、青岛润达、鑫海润邦；六家控股子公司：合肥润 达、武汉优科 ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 42.91 million and 51.49 million yuan, a decrease of 22.18 million to 23.04 million yuan compared to the previous year, representing a decline of 81.16% to 84.30%[5] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 21.97 million and 26.36 million yuan, down by 12.30 million to 12.74 million yuan year-on-year, reflecting a decrease of 82.36% to 85.29%[5] - The financial data in the performance forecast has not been audited by a registered accountant[6] - The forecast data is preliminary and subject to change, with the final audited financial data to be disclosed in the company's annual report for 2024[11] - The company emphasizes that there are no significant uncertainties affecting the accuracy of this performance forecast[10] Historical Financial Performance - In 2023, the company achieved a total profit of 655.56 million yuan, with a net profit attributable to shareholders of the parent company of 273.30 million yuan[8] - The company reported earnings per share of 0.47 yuan for the year 2023[8] Factors Affecting Profitability - The significant decrease in net profit is primarily due to the impact of domestic macroeconomic conditions and centralized procurement policies, which affected business development and sales revenue[9] - Fixed costs, such as service costs and depreciation of fixed assets, have not decreased, leading to increased marginal costs and expenses[9] - The collection period for accounts receivable from end customers has lengthened, resulting in credit impairment losses that significantly impacted the net profit attributable to shareholders of the parent company[9]

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2025-001 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 可转债发行上市概况 （一）经中国证券监督管理委员会证监许可[2020]586 号文核准，上海润达 医疗科技股份有限公司于 2020 年 6 月 17 日公开发行了 5,500,000 张（550,000 手）可转换公司债券，每张面值 100 元，发行总额 55,000 万元，发行期限 6 年， 票面利率分别为：第一年 0.3%、第二年 0.6%、第三年 1.0%、第四年 1.5%、第 五年 1.8%、第六年 2.0%。 （二）经上海证券交易所"[2020]185 号"自律监管决定书同意，公司 55,000 万元可转换公司债券于 2020 年 7 月 13 日起在上海证券交易所上市交易，债券简 ...

Group 1 - The core point of the article is that RunDa Medical plans to establish a venture capital fund focused on the healthcare sector, in collaboration with several partners [1] - The total committed capital for the venture capital fund is 134 million yuan, with RunDa Medical contributing 26.8 million yuan, representing 20% of the total [1]

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 | 2024-066 | | --- | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | | 上海润达医疗科技股份有限公司 关于与专业投资机构共同投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、对外投资概述 为进一步推动公司战略发展和投资布局，借助专业投资机构的资源优势，在 不影响公司日常经营发展和有效控制投资风险的前提下，公司计划与上海致凯资 产管理有限公司（以下简称"致凯资产"）、福州新投创业投资有限公司（以下简 称"福州新投"）、福建贝瑞和康基因技术有限公司（以下简称"福建贝瑞"）、上 投资标的名称：福州新投致凯瑞康创业投资基金合伙企业（有限合伙） （具体以市场监督管理部门核准的名称为准，以下简称"创业投资基金" 或"合伙企业"） 投资金额：上海润达医疗科技股份有限公司（以下简称"公司"）作为 有限合伙人以自有资金拟认缴出资额人民币 2,680 万元，占基金份额的 20.0 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2024-065 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (五)公司董事、监事和董事会秘书的出席情况 1、 公司在任董事 11 人，出席 11 人，公司董事姚沈杰、董事周晓兰、独立董事 王晶晶、独立董事 CHAN HWANG TONG、独立董事冯国富因工作原因未能 现场出席，以通讯方式参加本次会议； 二、 议案审议情况 (一) 非累积投票议案 1、 议案名称：关于变更会计师事务所的议案 一、 会议召开和出席情况 (一)股东大会召开的时间：2024 年 12 月 20 日 (二)股东大会召开的地点：上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的 ...

上海泽昌律师事务所 关于上海润达医疗科技股份有限公司 2024年第三次临时股东大会的 法律意见书 上海市浦东新区世纪大道 1589 号长泰国际金融大厦 11 层 电话：021-61913137 传真：021-61913139 邮编：200122 上海泽昌律师事务所 法律意见书 上海泽昌律师事务所 关于上海润达医疗科技股份有限公司 2024 年第三次临时股东大会的 法律意见书 泽昌证字 2024-01-02-09 致：上海润达医疗科技股份有限公司 上海泽昌律师事务所（以下简称"本所"）接受上海润达医疗科技股份有限公 司（以下简称"公司"）委托，就公司召开 2024 年第三次临时股东大会（以下简 称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）中国证券监督管理 委员会发布的《上市公司股东大会规则》（以下简称"《股东大会规则》"）等法律、 法规、规章和其他规范性文件以及《上海润达医疗科技股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律 ...